Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis.
Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentially irreversible ocular damage. However, the rise in ocular methicillin- resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance for patients with other ocular bacterial infections mandate the need for new agents targeted for ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treatment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. This specifically precludes any bacterial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications.
Comstock
Timothy L
TL
Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA. tcomstock@bausch.com
Karpecki
Paul M
PM
Morris
Timothy W
TW
Zhang
Jin-Zhong
JZ
Curr Med Res Opin. 2009 May;25(5):1159-69
19323612
Clin Ther. 2001 Aug;23(8):1296-310
11558866
Ophthalmology. 2008 Jan;115(1):51-6
17572497
Ophthalmology. 1999 Jul;106(7):1313-8
10406613
J Chemother. 2007 Apr;19(2):146-51
17434822
Surv Ophthalmol. 2004 Mar;49 Suppl 2:S79-83
15028483
Lancet Infect Dis. 2003 Jun;3(6):359-71
12781508
J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):570-4
19589772
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):105-10
18417430
Antimicrob Agents Chemother. 2009 Aug;53(8):3552-60
19506065
Am Fam Physician. 1998 Feb 15;57(4):735-46
9490996
J Pediatr Ophthalmol Strabismus. 2008 Mar-Apr;45(2):78-84
18404954
J Ocul Pharmacol Ther. 2007 Jun;23(3):243-56
17593008
J Antimicrob Chemother. 2009 Mar;63(3):443-50
19147516
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9
17652708
J Cataract Refract Surg. 2008 May;34(5):814-8
18471638
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001211
16625540
Cleve Clin J Med. 2008 Jul;75(7):507-12
18646586
J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44
19492955
Clin Ther. 2009 Mar;31(3):514-26
19393842
Ophthalmology. 2009 Sep;116(9):1615-1623.e1
19643483
Clin Microbiol Rev. 1999 Jan;12(1):147-79
9880479
Am J Ophthalmol. 2008 Jun;145(6):951-958
18374299